-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fabre disease is a congenital metabolic disease caused by The X-chain gene defect, which manifests itself as a significant decrease or loss of the activity of alpha-semilaccosidease abody in the patient's body, resulting in the pathological accumulation of glycolipids in the lysosomes of various tissue cells.
the disease originated in the fetus and accompanied by the patient's gradual deterioration throughout life, causing the failure of heart, kidney and other important organs.
2018 the disease is included in the country's first list of rare diseases, is a serious life-threatening disease and there is no effective treatment in the country.
injection of Agaglyse beta is sanofi (China) Investment Co., Ltd. agent Genzyme Europe B.V. to declare, and was included in the country's second batch of clinically urgently needed new drugs list.
the State Drug Administration shall, in accordance with the relevant provisions of the Notice on Optimizing the Review and Approval of Drug Registration, incorporate it into the priority review of the varieties and approve its import registration application in accordance with the data of overseas clinical trials and the characteristics of the product in the light of the validity and safety characteristics of the product.
approved listing of this product will bring good news to the treatment of patients with domestic law.
.